126. Capell HA, Porter DR, Madhok R. Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient? *Ann Rheum Dis* 1993; 52: 423-8
127. Capell HA, Brzeski M. Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis. *Ann Rheum Dis* 1992; 51: 424-9
128. Emery P, Luqmani R, Gordon C. Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts. *Br J Clin Pract* 1994; 48: 82-6
129. Creinin MD. Methotrexate and misoprostil for abortion at 57-63 days gestation. *Contraception* 1994; 50: 511-5
130. Creinin MD, Vittinghoff E. Methotrexate and misoprostol vs misoprostol alone for early abortion. *JAMA* 1994; 272: 1190-5
131. Tariq S, Tariq SM. Methotrexate in rheumatoid arthritis: can current knowledge and experience justify its use as a first-line disease-modifying agent. *Postgrad Med J* 1993; 69: 775-80
132. Kozlowski RD, Steinbrunner JV, MacKenzie AH, et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. *Am J Med* 1990; 88: 589-92
133. Grindulis KA, McConkey B. Does sulphasalazine cause folate deficiency in rheumatoid arthritis? *Scand J Rheumatol* 1985; 14: 265-70
134. Clark NAC, Fisk NM. Minimal compliance with the Department of Health recommendation for routine folate prophylaxis to prevent neural tube defects. *Br J Obstet Gynaecol* 1994; 101: 709-10

Correspondence: *Christopher P. Rains*, Adis International, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

Erratum

Vol. 49, No. 3, page 427: In table IV the dosage of fluoxetine in the study by Alby et al. should read *F 20 mg/day*.

[Wilde MI, Benfield P. *Tianeptine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs* 1995; 49 (3): 411-439]